- Home
- PDO vs BCRX Comparison
PDO vs BCRX Comparison
Compare PDO & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDO
- BCRX
- Stock Information
- Founded
- PDO 2020
- BCRX 1986
- Country
- PDO United States
- BCRX United States
- Employees
- PDO N/A
- BCRX N/A
- Industry
- PDO Trusts Except Educational Religious and Charitable
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PDO Finance
- BCRX Health Care
- Exchange
- PDO Nasdaq
- BCRX Nasdaq
- Market Cap
- PDO 1.7B
- BCRX 1.8B
- IPO Year
- PDO N/A
- BCRX 1994
- Fundamental
- Price
- PDO $13.86
- BCRX $8.33
- Analyst Decision
- PDO
- BCRX Strong Buy
- Analyst Count
- PDO 0
- BCRX 10
- Target Price
- PDO N/A
- BCRX $16.70
- AVG Volume (30 Days)
- PDO 520.0K
- BCRX 2.7M
- Earning Date
- PDO 01-01-0001
- BCRX 08-04-2025
- Dividend Yield
- PDO 11.80%
- BCRX N/A
- EPS Growth
- PDO N/A
- BCRX N/A
- EPS
- PDO N/A
- BCRX N/A
- Revenue
- PDO N/A
- BCRX $557,506,000.00
- Revenue This Year
- PDO N/A
- BCRX $41.37
- Revenue Next Year
- PDO N/A
- BCRX $7.56
- P/E Ratio
- PDO N/A
- BCRX N/A
- Revenue Growth
- PDO N/A
- BCRX 45.85
- 52 Week Low
- PDO $10.65
- BCRX $6.02
- 52 Week High
- PDO $13.31
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- PDO 72.84
- BCRX 47.59
- Support Level
- PDO $13.64
- BCRX $8.40
- Resistance Level
- PDO $13.72
- BCRX $8.68
- Average True Range (ATR)
- PDO 0.06
- BCRX 0.20
- MACD
- PDO 0.01
- BCRX 0.04
- Stochastic Oscillator
- PDO 100.00
- BCRX 50.00
About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.